OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ABAT57

Abate AS Industries Ltd

Healthcare Facilities & ServicesVerified

Abate AS Industries maintains a strong liquidity position, with a current ratio of 2.66, indicating the company can cover its short-term obligations more than twice over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The company's debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal leverage. Free cash flow stands at INR 16.24 million, supporting operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 0.43% and a return on assets (ROA) of 0.35%, both below the typical thresholds for high-performing healthcare firms. The operating margin is 1.33% (INR 1.87 million operating income on INR 140.87 million revenue), and the net margin is 5.06% (INR 7.12 million net income on INR 140.87 million revenue), indicating modest profitability relative to industry peers. The company's revenue is concentrated in two Indian states, Kerala and Tamil Nadu, with no disclosed international operations or diversification across other domestic regions. This geographic concentration increases exposure to regional economic or regulatory shifts. The business is also segmented into healthcare services, equipment, and education, but no revenue breakdown by segment is available in the latest financials. Growth trajectory is limited by the company's small scale and low capital expenditure of INR -385,460, suggesting minimal investment in expansion or new facilities. Revenue of INR 140.87 million and net income of INR 7.12 million indicate a stable but non-accelerating business model. No forward-looking guidance is provided in the input data, so growth assumptions must be inferred from historical performance. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. The company has not disclosed any recent equity offerings or dilutive events, and no adjustments are noted in the valuation snapshot. Recent events include the latest financial filing, which shows a stable operating cash flow of INR 17.19 million and a free cash flow of INR 16.24 million. No material events such as regulatory actions, lawsuits, or major acquisitions are disclosed in the input data.

30-day price · ABAT-0.74 (-6.6%)
Low$9.35High$12.69Close$10.39As of15 May, 00:00 UTC
Profile
CompanyAbate AS Industries Ltd
TickerABAT.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Abate AS Industries Limited operates eye hospitals, optical stores, and educational institutions in Kerala and Tamil Nadu, generating revenue through healthcare services, equipment, and education.

Classification. Abate AS Industries is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Abate AS Industries maintains a strong liquidity position, with a current ratio of 2.66, indicating the company can cover its short-term obligations more than twice over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The company's debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal leverage. Free cash flow stands at INR 16.24 million, supporting operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 0.43% and a return on assets (ROA) of 0.35%, both below the typical thresholds for high-performing healthcare firms. The operating margin is 1.33% (INR 1.87 million operating income on INR 140.87 million revenue), and the net margin is 5.06% (INR 7.12 million net income on INR 140.87 million revenue), indicating modest profitability relative to industry peers. The company's revenue is concentrated in two Indian states, Kerala and Tamil Nadu, with no disclosed international operations or diversification across other domestic regions. This geographic concentration increases exposure to regional economic or regulatory shifts. The business is also segmented into healthcare services, equipment, and education, but no revenue breakdown by segment is available in the latest financials. Growth trajectory is limited by the company's small scale and low capital expenditure of INR -385,460, suggesting minimal investment in expansion or new facilities. Revenue of INR 140.87 million and net income of INR 7.12 million indicate a stable but non-accelerating business model. No forward-looking guidance is provided in the input data, so growth assumptions must be inferred from historical performance. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. The company has not disclosed any recent equity offerings or dilutive events, and no adjustments are noted in the valuation snapshot. Recent events include the latest financial filing, which shows a stable operating cash flow of INR 17.19 million and a free cash flow of INR 16.24 million. No material events such as regulatory actions, lawsuits, or major acquisitions are disclosed in the input data.
Key takeaways
  • Abate AS Industries has a conservative capital structure with a low debt-to-equity ratio of 0.06.
  • The company's ROE and ROA are below typical thresholds for healthcare firms, indicating modest returns.
  • Revenue is concentrated in Kerala and Tamil Nadu, increasing regional exposure.
  • Free cash flow of INR 16.24 million supports operational flexibility but does not suggest aggressive reinvestment.
  • The company faces medium liquidity risk due to a negative net cash position after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$140.9M
Gross profit$31.0M
Operating income$1.9M
Net income$7.1M
R&D
SG&A
D&A
SBC
Operating cash flow$17.2M
CapEx-$385.5k
Free cash flow$16.2M
Total assets$2.06B
Total liabilities$418.5M
Total equity$1.64B
Cash & equivalents$16.1M
Long-term debt$105.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.64B
Net cash-$89.5M
Current ratio2.7
Debt/Equity0.1
ROA0.4%
ROE0.4%
Cash conversion2.4%
CapEx/Revenue-0.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricABATActivity
Op margin1.3%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin5.1%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin22.0%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-0.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity6.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 06:43 UTC#b3f89f67
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 06:44 UTCJob: 37d627d7